...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Rampant bull on the science, but some concerns over the money end linger.

KBC, we have not heard much from you for a very very long time on RVX.

Where do you stand on it? And are you still invested in it?

Your comments please if you don't mind.

 

Koo

Share
New Message
Please login to post a reply